Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744346 | 1.00 | DPP4 (0.42) | DPP4DPP7DPP8DPP9CYP3A4 | |
| SCHEMBL16750215 | 1.00 | DPP4 (0.42) | DPP4DPP7DPP8DPP9CYP3A4 | |
| SCHEMBL20008502 | 0.87 | DPP4 (0.42) | DPP4DPP7DPP8DPP9CYP3A4 | |
| SCHEMBL7932108 | 0.85 | DPP4 (0.40) | DPP4DPP7DPP8DPP9CYP3A4 | |
| SCHEMBL25075296 | 0.84 | DPP4 (0.40) | DPP4DPP7DPP8DPP9CYP3A4 | |
| SCHEMBL15108795 | 0.84 | DPP4 (0.40) | DPP4DPP7DPP8DPP9CYP3A4 | |
| SCHEMBL22950650 | 0.84 | DPP4 (0.46) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL22950652 | 0.84 | DPP4 (0.46) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL15103376 | 0.84 | DPP4 (0.40) | DPP4DPP7DPP8DPP9CYP3A4 | |
| SCHEMBL13005310 | 0.84 | DPP4 (0.46) | DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108598-A1 | SITAGLIPTIN SYNTHESIS | MYLAN INDIA PRIVATE LIMITED (IN) | 2012-05-03 | — | — | US | claimed |
| US-20180086765-A1 | NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME | KYUNG DONG PHARM. CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
| US-20160194680-A1 | Enzymatic Route For The Preparation Of Chiral Gamma-Aryl-Beta-Aminobutyric Acid Derivatives | LEK PHARMACEUTICALS D.D. (SI) | 2016-07-07 | — | — | US | disclosed |
| US-9249109-B2 | Method for preparing dipeptidyl peptidase-IV inhibitor and intermediate | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2016-02-02 | — | — | US | disclosed |
| US-9187419-B2 | Intermediates of sitagliptin and preparation process thereof | ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD. (CN) | 2015-11-17 | — | — | US | disclosed |
| US-20150025241-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2015-01-22 | — | — | US | disclosed |
| US-8846916-B2 | Sitagliptin synthesis | GENERICS [UK] LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-8846916-B2 | Sitagliptin synthesis | GENERICS [UK] LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-20130281695-A1 | INTERMEDIATES OF SITAGLIPTIN AND PREPARATION PROCESS THEREOF | ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD. (CN) | 2013-10-24 | — | — | US | disclosed |
| US-8334385-B2 | Process for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof | GLENMARK GENERICS LIMITED | 2012-12-18 | — | — | US | disclosed |
| US-20120108598-A1 | SITAGLIPTIN SYNTHESIS | MYLAN INDIA PRIVATE LIMITED (IN) | 2012-05-03 | — | — | US | disclosed |
| US-20120108598-A1 | SITAGLIPTIN SYNTHESIS | MYLAN INDIA PRIVATE LIMITED (IN) | 2012-05-03 | — | — | US | disclosed |
| EP-2430025-A1 | SITAGLIPTIN SYNTHESIS | Generics [UK] Limited (GB) | 2012-03-21 | — | — | EP | disclosed |
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
| US-8030315-B2 | DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity | DONG-A PHARM. CO., LTD. (KR) | 2011-10-04 | — | — | US | disclosed |
| US-20100317856-A1 | PROCESS FOR THE PREPARATION OF R-SITAGLIPTIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | GLENMARK GENERICS LTD (IN) | 2010-12-16 | — | — | US | disclosed |
| US-20100120790-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY | DONG-A PHARM. CO., LTD (KR) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025241-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 4/4885 |
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 5/4885 |
| US-20180086765-A1 | NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME | DPP4, DPP7, DPP9 | DPP4 1/4885DPP7 2/4885DPP8 4/4885 |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 4/4885 |
| US-20120108598-A1 | SITAGLIPTIN SYNTHESIS | DPP4, DPP7, DPP3 | DPP4 1/4885DPP7 2/4885DPP8 5/4885 |
| US-20100317856-A1 | PROCESS FOR THE PREPARATION OF R-SITAGLIPTIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | DPP4, DPP9, DPP3 | DPP4 1/4885DPP7 4/4885DPP8 5/4885 |
| US-20100120790-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY | DPP4, DPP7, DPP3 | DPP4 1/4885DPP7 2/4885DPP8 5/4885 |
| US-20130281695-A1 | INTERMEDIATES OF SITAGLIPTIN AND PREPARATION PROCESS THEREOF | DPP4, DPP9, DPP3 | DPP4 1/4885DPP7 4/4885DPP8 5/4885 |
| US-20160194680-A1 | Enzymatic Route For The Preparation Of Chiral Gamma-Aryl-Beta-Aminobutyric Acid Derivatives | GABRB1, GABRB2, GABRB3 | DPP4 431/4885DPP7 262/4885DPP8 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.